Self-measured blood pressure readings may be better predictors of cardiovascular issues or death than conventional blood pressure measurements, except among people with severe hypertension, according to a study published in the January issue of PLOS Medicine.

Bioresorbable drug-eluting scaffolding appears to be safe and effective in patients with iliac and femoral artery lesions, based on six-month results in the first-in-man ESPRIT trial presented Jan. 22 at the International Symposium on Endovascular Therapy in Miami Beach, Fla. 

Covidien pulled the plug on its renal denervation initiative, citing “slower than expected development of the renal denervation market.”

The Mediterranean diet may lower the risk of peripheral artery disease (PAD), according to results published in a research letter in the Jan. 22-29 issue of JAMA.

Three common carotid stenting systems used in the U.S. were associated with low rates of adverse events, a study published online Jan. 15 in JACC: Cardiovascular Interventions found.

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the New Drug Application (NDA) for its investigational, oral, once-daily direct factor Xa-inhibitor SAVAYSATM (edoxaban) Tablets has been submitted to the U.S. Food and Drug Administration (FDA). In the U.S., Daiichi Sankyo is seeking approval for edoxaban for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF), as well as for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and for the prevention of recurrence of symptomatic venous thromboembolism (VTE). SAVAYSA is the proposed brand name for edoxaban if approved for marketing in the U.S.

Although the novel oral anticoagulants dabigatran, rivaroxaban and apixaban offer alternatives to warfarin to prevent strokes in patients with atrial fibrillation, physicians may still need guidance on how to manage them.

The pivotal SYMPLICITY HTN-3 clinical trial designed to evaluate the safety and efficacy of renal denervation as a treatment for uncontrolled hypertension failed to meet its primary efficacy endpoint.